Literature DB >> 11720249

Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men.

V R Panz1, B I Joffe, I Spitz, T Lindenberg, A Farkas, M Haffejee.   

Abstract

The most common malignancy in men worldwide is cancer of the prostate. Androgens play a direct role in normal and malignant growth of prostate cells via the androgen receptor (AR). This study analyzed the polymorphic CAG repeat sequence in exon 1 of the AR gene to determine if the number of repeats might be an indicator of prostate cancer risk or aggressive disease. DNA was extracted from blood samples of 20 black and 20 white men with well-documented prostate cancer and 40 healthy controls (20 blacks and 20 whites). PCR amplification was followed by gel electrophoresis and DNA sequencing. This region normally contains between 9 and 29 repeats. Patients and controls both had minor variations in the number of repeats, which ranged from 13 to 27 with 21 being the most frequent allele. Black controls and patients both had a mean of 20 +/- 3 repeats; in whites the mean was significantly lower in patients than controls (21 +/- 2 versus 23 +/- 2; p = 0.004). Combined black and white patients also had a lower number than the combined group of controls (20 +/- 3 versus 22 +/- 3; p = 0.02). Similarly, black and white patients with aggressive disease had a lower number than patients whose disease was more slowly progressive (19 +/- 2 versus 22 +/- 3; p = 0.02). We conclude that the small differences in the number of CAG repeats in both black and white patients do not appear to be a strong indicator of risk or aggressive disease but that this size polymorphism may be one of many genetic and environmental risk factors involved in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720249     DOI: 10.1385/ENDO:15:2:213

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  21 in total

Review 1.  Hormonal signaling in prostatic hyperplasia and neoplasia.

Authors:  M Marcelli; G R Cunningham
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

2.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.

Authors:  A R La Spada; E M Wilson; D B Lubahn; A E Harding; K H Fischbeck
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

3.  Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups.

Authors:  A Edwards; H A Hammond; L Jin; C T Caskey; R Chakraborty
Journal:  Genomics       Date:  1992-02       Impact factor: 5.736

4.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

5.  Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.

Authors:  J L Stanford; J J Just; M Gibbs; K G Wicklund; C L Neal; B A Blumenstein; E A Ostrander
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

6.  Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer.

Authors:  M Ribeiro; P Ruff; G Falkson
Journal:  Am J Clin Oncol       Date:  1997-12       Impact factor: 2.339

7.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization.

Authors:  G Jenster; H A van der Korput; C van Vroonhoven; T H van der Kwast; J Trapman; A O Brinkmann
Journal:  Mol Endocrinol       Date:  1991-10

8.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer.

Authors:  R A Irvine; M C Yu; R K Ross; G A Coetzee
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

9.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.

Authors:  N L Chamberlain; E D Driver; R L Miesfeld
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

10.  CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk.

Authors:  O Bratt; A Borg; U Kristoffersson; R Lundgren; Q X Zhang; H Olsson
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

View more
  6 in total

Review 1.  Androgen receptor signaling and mutations in prostate cancer.

Authors:  Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2010-08-16       Impact factor: 3.285

2.  Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study.

Authors:  Matthew L Freedman; Celeste L Pearce; Kathryn L Penney; Joel N Hirschhorn; Laurence N Kolonel; Brian E Henderson; David Altshuler
Journal:  Am J Hum Genet       Date:  2004-11-29       Impact factor: 11.025

Review 3.  Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population.

Authors:  Scott M Gilbert; Mitchell C Benson; James M McKiernan
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 3.092

Review 4.  Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis.

Authors:  Zhiqiang Qin; Xiao Li; Peng Han; Yuxiao Zheng; Hanyu Liu; Jingyuan Tang; Chengdi Yang; Jianzhong Zhang; Kunpeng Wang; Xiaokang Qi; Min Tang; Wei Wang; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.

Authors:  Hong Weng; Sheng Li; Jing-Yu Huang; Zi-Qi He; Xiang-Yu Meng; Yue Cao; Cheng Fang; Xian-Tao Zeng
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

6.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.